Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Clone||NY-BR-1 No. 2|
|Immunogen||A 77 aa peptide from human NYBR-1 protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||1:100|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
MA5-12645 targets NY-BR-1 in IHC (P, F) applications and shows reactivity with Human samples.
The MA5-12645 immunogen is a 77 aa peptide from human NYBR-1 protein.
NY-BR-1 is a novel differentiation marker predominantly expressed in normal breast and breast cancer. It has been shown by Immunohistochemistry (IHC) that NY-BR-1 was present solely in ductal epithelium of normal breast tissue. Invasive carcinoma of the breast and carcinoma in situ were positive for NY-BR-1, whereas most other tumors and normal tissues are negative, with the exceptions of one-third of sweat gland carcinomas and around two percent of prostate carcinoma. NY-BR-1 is reported to express more frequently in estrogen-positive and lymph node-negative primary carcinomas, and more commonly in grade 1 than in grade 2 or grade 3. In a study by Varga et al (2006) forty-nine percent of lymph node metastasis were shown to be positive.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
MA5-12645 was used in immunohistochemistry to study NY-BR-1 and PAX8 immunoreactivity in CK7+ carcinomas and utility in determining the site of origin
|Woodard AH,Yu J,Dabbs DJ,Beriwal S,Florea AV,Elishaev E,Davison JM,Krasinskas AM,Bhargava R||American journal of clinical pathology (136:428)||2011|
Ankyrin repeat domain-containing protein 30A; breast cancer antigen NY-BR-1; Serologically defined breast cancer antigen NY-BR-1